Mucosolvan Max (Ambroxol Hydrochloride)

Ambroxol stimulates serous cells in the airway epithelium, increasing the secretion of thin, watery fluid. This reduces the viscosity of mucus, enhances ciliary movement, and promotes more efficient mucociliary clearance, making it easier for patients to expectorate secretions and relieve airway obstruction.

The appropriate dose of Mucosolvan Max is determined by a qualified healthcare professional based on the patient’s age, weight, severity of the condition, and renal function. Prescribers set the regimen according to clinical guidelines and individual patient needs.

Safety data for ambroxol during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using Mucosolvan Max.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ambroxol, the active ingredient in Mucosolvan Max, is distinguished by its dual action of stimulating serous secretion and reducing mucus viscosity. Compared with agents such as N‑acetylcysteine, ambroxol often provides a more rapid improvement in sputum clearance and may have a more favorable tolerability profile, though choice of therapy depends on individual patient factors and clinical judgment.

Mucosolvan Max should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mucosolvan Max is taken orally, usually with a glass of water. The tablet (or liquid, if applicable) should be swallowed whole and not chewed or crushed unless directed by a healthcare professional. Administration timing may be adjusted based on the prescriber’s instructions and patient convenience.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome, angioedema, and significant hepatic enzyme elevations. Patients should seek immediate medical attention if they experience symptoms like rash, swelling of the face or throat, difficulty breathing, or jaundice.

Mucosolvan Max should be avoided in individuals with a known hypersensitivity to ambroxol or any component of the formulation. Caution is also advised for patients with severe renal impairment, uncontrolled asthma, or those taking medications that may interact significantly with ambroxol. A healthcare professional should evaluate suitability before initiating therapy.